Xarelto bleeding claims continue to mount in the federal multidistrict litigation now underway in the U.S. district Court, Eastern District of Louisiana. According to court documents, more than 4,500 cases were pending in the proceeding as of April 15, 2016.

One of the most recent Xarelto lawsuits was filed on behalf of an Ohio man who allegedly died from serious internal bleeding less than a year after he was prescribed the blood-thinning medication. His family is seeking compensation for his alleged wrongful death, as well as fraud, breach of warranty, design defect, failure to warn, and negligent misrepresentation.

According to the April 8th complaint, the Decedent began taking Xarelto in December 2013, and continued using the drug until August 2014. On April 9, 2014, he suffered gastrointestinal bleeding that his family claims was the direct and proximate result of his Xarelto use.  (Case No. 2:16-cv-02913)

Allegations Put Forth by Xarelto Plaintiffs

Xarelto was approved by the U.S. Food & Drug Administration (FDA) in 2011. It is currently indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like any blood thinner, Xarelto can sometimes cause internal bleeding. However, there is currently no approved antidote for reversing this potentially deadly complication. By contrast, bleeding associated with a much older blood thinner called warfarin can be stopped via the administration of Vitamin K.

All of the Xarelto lawsuits now pending in the Eastern District of Louisiana claim that the drug’s manufacturers failed to provide adequate warnings regarding uncontrollable internal bleeding and other serious side effects, including strokes, deep vein thrombosis and pulmonary embolism, allegedly associated with its use. Plaintiffs also assert that the drug makers wrongly promoted Xarelto as a superior alternative to warfarin, considering its lack of a reversal agent for internal bleeding.

The Xarelto litigation is scheduled to convene a series of bellwether trials beginning in February 2017. These trials will be closely watched by other plaintiffs, as the outcomes in the cases could provide valuable insight into jury decisions in similar Xarelto lawsuits.

Bernstein Liebhard LLP is currently representing clients in Xarelto bleeding claims. If you are interested in filing a similar lawsuit, please contact our office by calling 877-779-1414.

Published May 10, 2016 by